We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead Sciences has secured an antiviral deal with Novartis to gain exclusive global rights to preclinical programmes involving candidates for the treatment of various viral infections.